MedTrace Logo

Post Transplant Donor Lymphocyte Infusion

NCT00167180 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2019-07-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the hypothesis that a pre-infusion preparative regimen of cyclophosphamide and fludarabine will improve the effectiveness of DLI in patients with blood cancers.

Conditions

Interventions

PROCEDURE

Donor Lymphocyte Infusion

donor cells infused over 2 hrs at cell dose of 0.5 dx 10\^8 CD3+T-cells/kg

DRUG

Induction Chemotherapy

Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV

Sponsors & Collaborators

  • Masonic Cancer Center, University of Minnesota

    lead OTHER

Principal Investigators

  • Jeffrey Miller, MD · Masonic Cancer Center, University of Minnesota

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2017-11-21
Completion
2018-12-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00167180 on ClinicalTrials.gov